Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases
January 27, 2020 08:58 ET
|
Akari Therapeutics Plc
•The new data show PAS-nomacopan (the long acting form of Akari’s lead drug, nomacopan) significantly reduced VEGF levels and retinal inflammation, both of which are associated with permanent damage...
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
January 10, 2020 09:29 ET
|
Akari Therapeutics Plc
Phase III interim data on the first eight PNH patients who were all transfusion dependent at entry to the CAPSTONE trial show that all four patients randomized to nomacopan were transfusion...
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND
December 23, 2019 08:45 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting
December 02, 2019 08:30 ET
|
Akari Therapeutics Plc
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based...
Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress
November 04, 2019 08:33 ET
|
Akari Therapeutics Plc
- New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration (FDA)-approved treatments for...
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial
October 14, 2019 08:37 ET
|
Akari Therapeutics Plc
Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported findingThese new findings suggest that...
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
October 10, 2019 08:45 ET
|
Akari Therapeutics Plc
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients– No reported drug-related serious adverse...
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
September 18, 2019 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
September 13, 2019 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September
September 03, 2019 07:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...